with JEG-3 choriocarcinoma cells demonstrated a similar ef- fect on D3 mRNA at 10 and 100 nM T3 (P < 0.01). The demon- strated changes in iodothyronine ...
0021-972X/03/$15.00/0 Printed in U.S.A.
The Journal of Clinical Endocrinology & Metabolism 88(9):4488 – 4495 Copyright © 2003 by The Endocrine Society doi: 10.1210/jc.2003-030228
Placental Iodothyronine Deiodinase Expression in Normal and Growth-Restricted Human Pregnancies S. CHAN, S. KACHILELE, E. HOBBS, J. N. BULMER, K. BOELAERT, C. J. MCCABE, P. M. DRIVER, A. R. BRADWELL, M. KESTER, T. J. VISSER, J. A. FRANKLYN, AND M. D. KILBY Department of Fetal Medicine, Division of Reproductive and Child Health (S.C., S.K., E.H., M.D.K.), Department of Medical Sciences (K.B., C.J.M., P.M.D., A.R.B., J.A.F.), University of Birmingham, Birmingham, United Kingdom B15 2TG; Department of Pathology, University of Newcastle-upon-Tyne (J.N.B.), Newcastle-upon-Tyne, NE1 4LP United Kingdom; and Department of Internal Medicine III, Erasmus University Medical School (M.K., T.J.V.), 3015 GE Rotterdam, The Netherlands We have described the expression of specific iodothyronine deiodinase mRNAs (using quantitative RT-PCR) and activities in normal human placentas throughout gestation and compared our findings to those in placentas from pregnancies affected by intrauterine growth restriction (IUGR). The predominant deiodinase expressed in placenta was type III (D3); type II (D2) was also present. In general terms, the activities of the enzymes D2 and D3 (and mRNAs encoding these enzymes) were higher earlier in gestation (
